$IMRX News

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

Immuneering Has Promising Survival Data, Though Its Cash Discount Needs Scrutiny

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Immuneering to Present at the ESMO Congress 2026

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development

Immuneering to Participate in Upcoming Investor Conferences

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment

HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Immuneering Q2 EPS $(0.27), Inline

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors

Needham Maintains Buy on Immuneering, Raises Price Target to $18

Immuneering Corporation Announces Grants of Inducement Awards

Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know

Cantor Fitzgerald Initiates Coverage On Immuneering with Overweight Rating

Immuneering Appoints Andrew Gengos CFO, Effective July 16